Literature DB >> 6170726

Experimental infection of inbred mice with herpes simplex virus. II. Interferon production and activation of natural killer cells in the peritoneal exudate.

H Engler, R Zawatzky, A Goldbach, C H Schröder, C Weyand, G J Hämmerling, H Kirchner.   

Abstract

The peritoneal exudate cells (PEC) represent the first line of defence against the virus in the mouse model of intraperitoneal (i.p.) infection with herpes simplex virus (HSV). We have therefore studied interferon production and activation of natural killer (NK) cells in vitro in PEC of HSV-injected mice. Injection of HSV caused a marked increase in NK cell activity, as reported by others. PEC from HSV-injected mice also produced high titres of interferon. This observation may be important since induction of interferon appears to be the primary event whereas activation of NK cells - as generally accepted - represents a secondary effect of the interferon produced. The HSV-induced NK cells shared the properties of NK cells in that they were sensitive to a monoclonal anti-theta antibody and to a monoclonal anti-Qa 5 antibody. In contrast, the cells producing interferon were not sensitive to either antibody. Irradiation (200 R) of the mice 24 h before injection of the virus decreased interferon production by more than 90%. The identity of the interferon-producing cells is unknown, but they may represent B cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6170726     DOI: 10.1099/0022-1317-55-1-25

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  13 in total

1.  Monoclonal antibodies suppress replication of herpes simplex virus type 1 in trigeminal ganglia.

Authors:  J E Oakes; R N Lausch
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

2.  Activation of natural killer cells and induction of interferon after injection of mouse hepatitis virus type 3 in mice.

Authors:  L Schindler; H Engler; H Kirchner
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

Review 3.  Animal models of herpes simplex virus immunity and pathogenesis.

Authors:  Christina M Kollias; Richard B Huneke; Brian Wigdahl; Stephen R Jennings
Journal:  J Neurovirol       Date:  2014-11-12       Impact factor: 2.643

4.  Interleukin-3 protects mice from acute herpes simplex virus infection.

Authors:  W L Chan; H J Ziltener; F Y Liew
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

5.  Modulation of acute and latent herpes simplex virus infection in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activity.

Authors:  R H Bonneau; S R Jennings
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

6.  Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2.

Authors:  M R McDermott; J R Smiley; P Leslie; J Brais; H E Rudzroga; J Bienenstock
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

7.  Expression of immunity to intravaginal herpes simplex virus type 2 infection in the genital tract and associated lymph nodes.

Authors:  M R McDermott; P L Brais; G C PLoettsche; M J Evelegh; C H Goldsmith
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

8.  Effect of anti-CXCL10 monoclonal antibody on herpes simplex virus type 1 keratitis and retinal infection.

Authors:  Daniel J J Carr; James Chodosh; John Ash; Thomas E Lane
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication.

Authors:  Peter Härle; Vanessa Cull; Martin-Paul Agbaga; Robert Silverman; Bryan R G Williams; Cassandra James; Daniel J J Carr
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Experimental infection of inbred mice with herpes simplex virus. IV. Comparison of interferon production and natural killer cell activity in susceptible and resistant adult mice.

Authors:  H Engler; R Zawatzky; H Kirchner; D Armerding
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.